Latest News About - Gastroenterology and urology devices

 
Show/hide duplicate news articles.
Filter by countryfromabout
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Friday, April 3, 2020

12:30:00 PM CEST

Subscribe
RSS | MAP

Language Selection

For any category/filter, users can choose:

  1. the language of the categorized news items (e.g. fr and de to display only those news items in French and German)
  2. the language of the user interface (e.g. it for Italian)

In Top Stories, the user can display the largest clusters of news items for one language only (e.g. en shows all clusters in English)

Country Selection

Users can choose:

  1. country mentioned in the news item (articles about a country)
  2. country in which the news item was published (articles from a country)

Languages Collapse menu...Expand menu...Open help...

Select your languages

ar
az
be
bg
bs
ca
cs
da
de
el
en
eo
es
et
fa
fi
fr
ga
gl
ha
he
hi
hr
hu
hy
id
is
it
ja
ka
km
ko
ku
ky
lb
lo
lt
lv
mk
ml
mn
ms
mt
nl
no
pap
pl
ps
pt
ro
ru
se
si
sk
sl
sq
sr
sv
sw
ta
th
tr
uk
ur
vi
zh
all
Show additional languagesHide additional languages

Interface:

Quotes... Extracted quotes

Bruce Neal told: "Usually because of the weather the way it is, a lot of people are going to be watching ... [their] NCAA basketball team," External link

medicinenet Sunday, March 29, 2020 8:44:00 AM CEST

Edward Markey said: "The United States simply cannot play radioactive roulette and gamble with public health and safety," External link

medicinenet Sunday, March 29, 2020 8:44:00 AM CEST

Giles Martin : “In 2019, following two years of intense M&A activity in 2017 and 2018, the Group moved into the final phase of its five year 2016-2020 plan to build a unique global network of state-of-the-art laboratories, market leadership positions, scale and scientific excellence to offer even better, faster, more cost effective and innovative services to its clients. From a financial perspective, this translated into lower investments, in terms of both M&A and Net capex, as well as continued improvement in the profitability of the mature business created or acquired before 2017, leading to improved free cash flow generation. Unfortunately, the Group suffered a criminal cyber-attack on 02 June 2019, which severely hit several Group laboratories and temporarily stopped or reduced production. This has significantly impacted the financial performance of the Group in 2019. While operations recovered for the most part within two weeks, many of Eurofins’ businesses were still feeling the negative impact of those service interruptions and the ensuing efforts to harden IT systems through H2 2019. Combined with the resulting defocus of management beyond the costs and revenue losses incurred, this cyber-attack has probably delayed progress towards the Group’s growth objectives by six months. Any lag should however be neutralised within 2020 and the IT spend normalised. The good performance achieved in Q4 in spite of this incident is encouraging and an indication of the dynamism and resilience of Eurofins’ health focused markets as well as Eurofins’ strong competitive position in those. The ongoing integration efforts following the exceptional M&A activity of 2017 and 2018 as well as investments into building an unmatched state-of-the-art laboratory platform (laboratory buildings, start-ups and IT) with significant scale advantages and consolidating businesses therein, continued to weigh on the overall margin and cash flow generation in 2019. In 2020, the Group’s focus will continue to be to finalise the internal investments required to complete this five year plan. In particular our focus will be on completing the planned site reorganisations and IT solutions deployment, making progress towards operational excellence, and, as a result, further improving profitability and cash flow generation, with a subsequent continued deleveraging of the balance sheet. Beyond 2020, once the 2016-2020 five year plan shall be completed, the Group expects to benefit from significantly improved competitive advantage and to be ready to enter its next growth cycle, which should be even more innovation led. After having achieved the expansion targets in North America announced in 2011, the Group will be more focused on expansion in Asia and Latin America. We believe that the operational benefits of all investments carried out in the 2016-2020 period should result in significantly improved profitability, cash flow generation and return on investment” External link

4-traders Wednesday, March 4, 2020 7:59:00 AM CET

Most associated names

Daily number of articles in this category

Trend data not available for this selection.